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Abstract
D2 procedure has been accepted in Far East as the 
standard treatment for both early (EGC) and advanced 
gastric cancer (AGC) for many decades. Recently 
EGC has been successfully treated with endoscopy 
by endoscopic mucosal resection or endoscopic 
submucosal dissection, when restricted or extended 
Gotoda's criteria can be applied and D1+ surgery is 
offered only to patients not fitted for less invasive 
treatment. Furthermore, two randomised controlled 
trials (RCTs) have been demonstrating the non infe-
riority of minimally invasive technique as compared to 
standard open surgery for the treatment of early cases 
and recently the feasibility of adequate D1+ dissection 
has been demonstrated also for the robot assisted 
technique. In case of AGC the debate on the extent 
of nodal dissection has been open for many decades. 
While D2 gastrectomy was performed as the standard 
procedure in eastern countries, mostly based on 
observational and retrospective studies, in the west the 
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Medical Research Council (MRC), Dutch and Italian RCTs 
have been conducted to show a survival benefit of D2 
over D1 with evidence based medicine. Unfortunately 
both the MRC and the Dutch trials failed to show a 
survival benefit after the D2 procedure, mostly due to 
the significant increase of postoperative morbidity and 
mortality, which was referred to splenopancreatectomy. 
Only 15 years after the conclusion of its accrual, the 
Dutch trial could report a significant decrease of recur­
rence after D2 procedure. Recently the long term 
survival analysis of the Italian RCT could demonstrate 
a benefit for patients with positive nodes treated with 
D2 gastrectomy without splenopancreatectomy. As 
nowadays also in western countries D2 procedure can 
be done safely with pancreas preserving technique and 
without preventive splenectomy, it has been suggested 
in several national guidelines as the recommended 
procedure for patients with AGC.
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Core tip: Recently early gastric cancer and advanced 
gastric cancer (AGC) has been successfully treated 
endoscopically; surgery is offered only to patients 
not fitted for less invasive treatment and in several 
guidelines D1+ (open, laparoscopic, robotic) is the 
adequate treatment. For AGC, while D2 gastrectomy 
is the standard procedure in eastern countries, mostly 
based on retrospective studies, in the west different 
randomised controlled trials have been conducted to 
demonstrate a survival benefit of D2 over D1 with 
evidence based medicine, with contradictory results. 
As nowadays D2 gastrectomy can be done safely 
with pancreas and spleen preservation, it has been 
suggested also in several western guidelines as the 
recommended procedure for patients with AGC.
Degiuli M, De Manzoni G, Di Leo A, D’Ugo D, Galasso E, 
Marrelli D, Petrioli R, Polom K, Roviello F, Santullo F, Morino M. 
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J Gastroenterol 2016; 22(10): 2875-2893 Available from: URL: 
http://www.wjgnet.com/1007-9327/full/v22/i10/2875.htm DOI: 
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INTRODUCTION
The Japanese Research Society for Gastric Cancer 
(JRSGC) published the first edition of the General Rules 
for Gastric Cancer Study in 1973[1]. In fact, several 
lymph node studies performed in the 50’s and 60’ in 
Japan revealed pathways of lymph node drainage. 
Following these studies, in the first English edition 
of the General Rules of JRSGC[2], which were widely 
accepted and adopted in many countries, regional 
lymph nodes were classified into 16 stations by their 
location (Table 1, Figure 1A).
In 1997, the JRSGC was transformed into the 
Japanese Gastric Cancer Association and this new 
association has maintained its commitment to the 
concept of the Japanese Classification. The aim of 
this classification is to provide a common language 
for the clinical and pathological description of gastric 
cancer. In the newest classification of the Japanese 
Gastric Cancer Association (JGCA), there is a very 
comprehensive description of regional lymph node, as 
follow[3].
Anatomical definition of lymph nodes and lymph node 
regions 
The regional lymph nodes of the stomach are classified 
into stations numbered as in Table 2, from 1 to 20, 
plus stations 110, 111 and 112. Some of lymph node 
stations numbered from 1 to 20 have been subdivided 
in further subsets of nodes (Figure 1b and C). Lymph 
node stations 1-12 and LN station 14v are defined as 
regional stations; the remnant lymph node stations are 
considered as distant stations and metastases to these 
nodes are classified as M1. Lymph nodes No. 19, 10, 
110 and 111 are considered as regional lymph nodes 
in case of tumor invading the esophagus.
Lymph node metastasis (N) are classified as 
follows: (1) NX: regional lymph nodes cannot be 
assessed; (2) N0: no regional lymph nodes metastasis; 
(3) N1: metastasis in 1-2 regional lymph nodes; (4) 
N2: metastasis in 3-6 regional lymph nodes; and (5) 
N3: metastasis in 7 or more regional lymph nodes; 
N3a, metastasis in 7-15 regional lymph nodes; N3b, 
metastasis in > 15 regional lymph nodes. In 2011 
the JGCA published the Japanese gastric cancer 
treatment guidelines 2010 (ver. 3)[4] based on the 3rd 
English edition of the Japanese Classification of Gastric 
Carcinoma[3], which defined the extent of systematic 
lymphadenectomy according to the type (distal or 
total) of gastrectomy indicated. These guidelines 
report which lymph node stations are expected to 
be removed to perform a correct D1, D1+ or D2 in 
case of both distal and total gastrectomy (see chapter 
“definition of different levels of lymph node dissection).
ANATOMICAL BORDERS OF LOCO-
REGIONAL LYMPH NODES
The strategy of lymph node dissection is based on 
a perfect knowledge of the anatomy of the upper 
abdominal vessels, which are usefull landmarks in the 
operating fields.
We will describe systematically all the locoregional 
lymph node stations, with particular regards to their 
anatomical and vascular borders.
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Location number 1 (right paracardial nodes) 
Perigastric lymph nodes on the right side of the cardia; 
they are located along the cardio-esophageal branch 
of the left gastric artery, from its origin from the left 
gastric artery to the oesophageal hiatus.
Location number 2 (left paracardial nodes)
Perigastric lymph nodes on the left side of the cardias, 
located along the cardio-oesophageal branch of the left 
inferior phrenic artery.
Location number 3 (lesser curvature nodes)
Perigastric lymph nodes at the lesser curvature, 
located along the inferior (descending) branch of the 
left gastric artery and along the right gastric artery 
distal to the first gastric branch.
Location number 4 (greater curvature nodes)
Perigastric lymph nodes at the greater curvature. 
This lymph node station is divided into a left (4s) and 
right (4d) part defined by the Von Ghoete point (the 
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Table 1  Numbering of lymph nodes according to the old classification of Japanese Research Society for Gastric Cancer (1962)
Station nr Station nr
1 Right cardiac nodes   9 Nodes around the coeliac axis
2 Left cardiac nodes 10 Nodes at the splenic hilus
3 Nodes along the lesser curvature 11 Nodes along the splenic artery
4 Nodes along the greater curvature 12 Nodes in the hepatoduodenal ligament
5 Suprapyloric nodes 13 Nodes at the posterior aspect of the pancreas head
6 Infrapyloric nodes 14 Nodes at the root of the mesenterium
7 Nodes along the left gastric artery 15 Nodes in the mesocolon of the transverse colon
8 Nodes along the common hepatic artery 16 Para-aortic lymph nodes
Figure 1  locations of lymph node station. A: Numbering and locations of lymph node station according to the first edition of the General Rules of the JRSGC; B: 
Location of lymph node stations in the posterior area; C: Location of lymph node stations in subphrenic area. JRSGC: Japanese Research Society for Gastric Cancer; 
APIS: Arteria phrenica inferior sinistra; AGB: Arteriae gastricae breves; AGES: Arteria gastroepiploica sinistra; VGED: Vena gastroepiploica dextra; VCDA: Vena colica 
dextra accessoria; VCM: Vena colica media; VCD: Vena colica dextra.
C
BA
111
110
112
19
VGED
VCDA
VCD
VCM
AGES
AGB
APIS
Degiuli M et al . Lymph node dissection in gastric cancer
Location number 7 (left gastric artery nodes)
Second tier lymph nodes located along the left gastric 
artery, from its origin from the coeliac trunk till its 
bifurcation into the cardioesophageal (ascending) and 
lower (descending) branches on the lesser curvature.
Location number 8 (common hepatic artery nodes)
Second tier nodes located around the common hepatic 
artery from its origin from the coeliac trunk to the 
branching off of the gastroduodenal artery. These 
lymph nodes are divided into an anterior part, 8a, and 
a posterior part, 8p (Figure 2).
Location number 9 (coeliac trunk nodes)
Second tier lymph nodes located around at the celiac 
axis including the origins of the common hepatic artery 
and splenic artery (Figure 2).
Location number 10 (splenic hilum nodes)
Second or third tier, or M lymph nodes, located at the 
point where right and left gastropepiploic arteries 
meet each other at full channel). Furthermore the left 
part is divided into a proximal (4sa) and a distal part 
(4sb). Lymph nodes of the proximal part of left group 
4 (4sa) are located around the short gastric arteries 
while lymph nodes of the distal part (4sb) are located 
along the left gastroepiploic artery. Lymph nodes of 
the right part of group 4 are located along the right 
gastroepiploic artery, distal to the first gastric branch. 
Location number 5 (suprapyloric nodes)
Perigastric lymph nodes at the lesser curvature, 
located at the origin of the right gastric artery including 
its first gastric branch. 
Location number 6 (infrapyloric nodes)
Perigastric lymph nodes at the greater curvature of the 
pylorus, located along the right gastroepipolic vessels 
from their origin from the gastroduodenal vessels till 
their first branches directed to the gastric wall.
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Table 2  Anatomical definitions of lymph node stations
Nr. Definition
1 Right paracardial LNs, including those along the first branch of the ascending limb of the left gastric artery
2 Left paracardial LNs including those along the esophagocardiac branch of the left subphrenic artery
3a Lesser curvature LNs along the branches of the left gastric artery
3b Lesser curvature LNs along the 2nd branch and distal part of the right gastric artery
4sa Left greater curvature LNs along the short gastric arteries (perigastric area)
4sb Left greater curvature LNs along the left gastroepiploic artery (perigastric area)
4d Rt. greater curvature LNs along the 2nd branch and distal part of the right gastroepiploic artery
5 Suprapyloric LNs along the 1st branch and proximal part of the right gastric artery
6 Infrapyloric LNs along the first branch and proximal part of the right gastroepiploic artery down to the confluence of the right gastroepiploic 
vein and the anterior superior pancreatoduodenal vein
7 LNs along the trunk of left gastric artery between its root and the origin of its ascending branch
8a Anterosuperior LNs along the common hepatic artery
8p Posterior LNs along the common hepatic artery
9 Coeliac artery
10 Splenic hilar LNs including those adjacent to the splenic artery distal to the pancreatic tail, and those on the roots of the short gastric arteries 
and those along the left gastroepiploic artery proximal to its 1st gastric branch
11p Proximal splenic artery LNs from its origin to halfway between its origin and the pancreatic tail end
11d Distal splenic artery LNs from halfway between its origin and the pancreatic tail end to the end of the pancreatic tail
12a Hepatoduodenal ligament LNs along the proper hepatic artery, in the caudal half between the confluence of the right and left hepatic ducts and 
the upper border of the pancreas
12b Hepatoduodenal ligament LNs along the bile duct, in the caudal half between the confluence of the right and left hepatic ducts and the upper 
border of the pancreas
12p Hepatoduodenal ligament LNs along the portal vein in the caudal half between the confluence of the right and left hepatic ducts and the upper 
border of the pancreas
13 LNs on the posterior surface of the pancreatic head cranial to the duodenal papilla
14v LNs along the superior mesenteric vein
15 LNs along the middle colic vessels
16a1 Paraaortic LNs in the diaphragmatic aortic hiatus
16a2 Paraaortic LNs between the upper margin of the origin of the celiac artery and the lower border of the left renal vein
16b1 Paraaortic LNs between the lower border of the left renal vein and the upper border of the origin of the inferior mesenteric artery
16b2 Paraaortic LNs between the upper border of the origin of the inferior mesenteric artery and the aortic bifurcation
17 LNs on the anterior surface of the pancreatic head beneath the pancreatic sheath
18 LNs along the inferior border of the pancreatic body
19 Infradiaphragmatic LNs predominantly along the subphrenic artery
20 Paraesophageal LNs in the diaphragmatic esophageal hiatus
110 Paraesophageal LNs in the lower thorax
111 Supradiaphragmatic LNs separate from the esophagus
112 Posterior mediastinal LNs separate from the esophagus and the esophageal hiatus
LNs: Lymph nodes.
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splenic hilus, distal to the tip of the pancreas tail. At 
the lower pole of the spleen, the first gastric branch 
of the left gastroepiploic artery defines the vascular 
border between 10 and 4sb lymph nodes. 
Location number 11 (splenic artery nodes)
Second tier nodes located along the splenic artery. 
These nodes have been divided into a proximal part, 
11p, located around the splenic artery, from its origin 
from the celiac axis, till the branching off of the posterior 
gastric artery; and into a distal part, 11d, located 
around the splenic artery from the branching off of the 
posterior gastric artery to the tip of the pancreas tail 
(Figure 2).
Location number 12 (hepatoduodenal ligament nodes)
Second and third tier nodes (according to the site of 
the primary tumor) at the hepatoduodenal ligament. 
These nodes have been divided into 3 parts: left 
hepatoduodenal ligament nodes (12a), located at the 
left side of the proper hepatic artery; and posterior 
hepatoduodenal ligament nodes (12b and 12p), again 
divided into nodes located at the right and posterior 
side of the common hepatic duct (12b) and into nodes 
located posteriorly to the portal vein (12p) (Figure 2). 
Location number 13 (retropancreatic nodes)
Third tier and M nodes, (according to the site of 
the primary tumor), along the superior and inferior 
branches of the posterior pancreaticoduodenal artery, 
located over the posterior side of the pancreas head. 
The left lateral border of this location is marked by the 
portal vein, while the upper border is represented by 
the origin of locations 12b and 12p. 
Location number 14 (superior mesenteric vein and 
artery nodes)
Second and third tier and M nodes (according to the 
site of the primary tumor) along the origin of the 
superior mesenteric vein (VMS) (14 v) and M nodes 
along the origin of the superior mesenteric artery (AMS), 
at the root of the mesenterium. The lateral border is 
represented by the branching of the gastrocolic vein 
(TGC); the lower border is located at the branching off 
of the middle colic vein from the VMS and the upper 
border is represented by the origin of the AMS at the 
lower hedge of the pancreas.
Location number 15 (middle colic nodes)
M nodes located in the transverse mesocolon around 
the middle colic vessels, from their origin from the 
superior mesenteric vessels, till the mesocolic hedge of 
the transverse colon.
Location number 16 (aortic hiatus -a1, middle -a2/b1 and 
caudal -b2 paraaortic nodes)
Location number 16 includes in fact 4 separate groups 
of lymph nodes. All of them are nodes around the 
abdominal aorta and inferior vena cava. The groups are 
the following: 16a1, M nodes around the aortic hiatus, 
over the anterior side of the aorta, from the inferior 
hedge of the hiatus to the upper border of the coeliac 
trunk; 16a2, M nodes located over the anterior side of 
the aorta, from the coeliac trunk to the lower hedge of 
the left renal vein; 16b1, third tier nodes located around 
the anterior face of the aorta and vena cava, from the 
lower hedge of the left renal vein to the upper border of 
the inferior mesenteric artery; right and left border are 
defined by the right hedge of the inferior vena cava and 
by the left ovarian (spermatic) vessels; 16b2, M nodes 
located around the anterior face of the aorta and vena 
cava, from the upper border of the inferior mesenteric 
artery to the aortic bifurcation (Figure 3). 
DEFINITIONS OF DIFFERENT LEVELS OF 
LYMPH NODE DISSECTION
In the Japanese gastric cancer treatment guidelines 
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Figure 3  Anatomical borders of lymph node station nr 16.Figure 2  Complete lymph node removal along the hepatic pedicle (lymph 
node station nr 12a, 12b and 12p), common hepatic artery (lymph node 
station nr 8a and 8p), splenic artery (lymph node station nr 11p), coeliac 
axis (lymph node station nr 9).
12a 9
8a
8p
11p
12p
12b
16a1
16a2
16b1
16b2
16a1
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2010 (ver. 3) based on the 3rd English edition of the 
Japanese Classification of Gastric Carcinoma, the JGCA 
defined the extent of systematic lymphadenectomy 
according to the type of gastrectomy indicated[4].
For total gastrectomy, the lymph nodes stations 
to be dissected in D1 lymphadenectomy are stations 
from No.1 to 7; D1+ includes D1 stations plus stations 
No.8a, 9, and 11p, and D2 includes D1 stations plus 
stations No.8a, 9, 10, 11p, 11d, and 12a. For tumors 
invading the esophagus, D1+ includes N0. 110 and D2 
includes Nos. 19,20,110 and 111.
For distal gastrectomy, the lymph nodes stations 
to be dissected in D1 lymphadenectomy are stations 
No.1, 3, 4sb, 4d, 5, 6 and 7; D1+ includes D1 stations 
plus stations No.8a, and 9, and D2 includes D1 
stations plus stations No.8a, 9, 11p, and 12a.
LYMPH NODE DISSECTION FOR EARLY 
GASTRIC CANCER
The extent of lymphadenectomy in early gastric 
cancer (EGC) is strongly dependent from lymph 
nodal spread of early forms. It is well known that 
the probability of lymph node metastasis in EGC 
is much lower than in advanced forms. However, 
the risk ranges notably according to pathological 
characteristics of EGC. Invasion of submucosa, tumor 
grading, size, macroscopic appearance, and lympho-
vascular invasion have been identified as strong risk 
factors for lymph node metastases in EGC[5]. As a 
consequence, these factors are taken into account for 
establishing the indications to endoscopic resection 
procedures (endoscopic mucosal resection, EMR, or 
endoscopic submucosal dissection, ESD) in the JGCA 
guidelines[4-6]. According to these predictive factors, 
subgroups of patients with virtual no risk of lymph 
node metastases have been identified. The resection is 
judged as curative when all of the following conditions 
are fulfilled: en-bloc resection, tumor size not greater 
than 2 cm, histology of intestinal-differentiated-type, 
pT1a, negative horizontal (lateral) margin, negative 
vertical margin, and no lymphovascular invasion. The 
JGCA “expanded” criteria tend to include larger tumor 
size, ulcerated or submucosal invading forms, and 
selected undifferentiated tumors in the indications to 
endoscopic treatment[7,8]. However, expanded criteria 
are not universally accepted and need validation in 
series outside East Asia[9].
In early forms not suitable for endoscopic treat-
ment, the JGCA guidelines advice a D1 or D1 plus 
lymphadenectomy in cases with clinically negative 
nodes[4]. The D1 lymphadenectomy involves the 
removal of perigastric lymph nodes and station 
number 7, whereas in the D1 plus the lymph node 
stations 8a and 9 for subtotal gastrectomy, with the 
addition of station 11p for total gastrectomy, should 
be dissected. When lymph nodes are clinically positive, 
JGCA treatment guidelines advice a D2 dissection, 
which involves the removal of stations 12a and 11p in 
subtotal gastrectomy, and stations 12a, 11d and 10 in 
total gastrectomy[4]. 
In South Korea the treatment approach to early 
forms is similar[10]. In a recent study from Seoul 
National University Hospital (SNUH) the appropriate 
extent of lymph node (LN) dissection in lower third 
was evaluated analysing LN metastasis patterns 
from a prospective topographic database, using 
the Maruyama Index of unresected disease[11]. The 
evaluated risk of lymph node metastasis in stations 
8-12 led the Authors to conclude that the D1 dissection 
plus stations 7 and 8a for mucosal cancer, and an 
expanded dissection to the D2 level for submucosal 
cancer should be considered to ensure complete 
removal of metastatic LNs.
In the West, the clinical setting is rather different 
from East Asia. In a large series of resected EGC from 
the Italian Research Group for Gastric Cancer (GIRCG) 
database, submucosal invasion, Lauren diffuse/mixed 
type, Kodama Pen A type and tumor size were found 
to be associated with an increased risk of lymph node 
metastases[12]. The risk of positive nodes is particularly 
high in diffuse-mixed type, an aggressive form of 
gastric cancer with special propensity to lymph node 
metastasis and peritoneal dissemination in advanced 
forms[13]. In the West, the decreasing incidence of 
gastric cancer is mainly due to the decreasing number 
of intestinal type tumors of the distal third; as such, 
proximal tumors and diffuse-mixed type show a 
relative increase, and surgeons will more frequently 
face with this aggressive form of gastric cancer[14,15]. 
Furthermore, endoscopic resections, which are 
treatment but also staging procedures, are much less 
adopted in the West, even if their implementation in 
clinical practice is increasing, above all in specialized 
centers[16]; as a consequence the diagnosis of EGC 
is clinically-based in most cases. Despite the recent 
advancement of staging procedures (CT scan, 
endoscopic US), the risk of a clinical understaging is 
still considerable, and this may be associated with a 
potentially fatal undertreatment, as the probability 
of advanced nodal status in non-early forms of 
gastric cancer in Western patients is notable[15]. For 
these reasons, the GIRCG guidelines advice a D2 
lymphadenectomy in clinically early forms not suitable 
for endoscopic treatment[17]. Special attention should 
be given to the removal of infra-pyloric nodes (number 
6), which are the most commonly involved in EGC 
of the distal stomach, above all in the diffuse-mixed 
type, and to station 1 (in subtotal gastrectomy) as well 
as to lymph node stations from 7 to 12 (station 10 is 
optional). The D2 dissection is associated with a limited 
risk of complications and postoperative mortality in 
the West, above all when performed in specialized 
centers and when avoiding unnecessary splenectomy 
or spleno-pancreatectomy[14,18]. Only in selected 
cases (high-risk patients, early forms with favourable 
pathological characteristics) more limited procedures 
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are adviced by the GIRCG group (D1 plus).
In any case, long term results reported in 
previous studies should be considered to optimize 
treatment approach. Surgical treatment with adequate 
lymphadenectomy could offer a high probability of 
cure even in Western patients. Survival rates in early 
stages reported from specialized Western centers are 
very similar to those obtained in Eastern series[19,20]. 
Selected forms can be treated by endoscopic approach, 
in accordance with the JGCA criteria, with acceptable 
results even in the West[16,21]. However, it should be 
emphasized that lymph node status is the strongest 
prognostic factor for EGC. Whereas 5-year and 
10-year cancer-related survival of 98% and 95% can 
be achieved in pT1N0 cases treated with appropriate 
lymphadenectomy, these rates fall to 70%-80% in 
pT1N1/N2, and less than 30% when more than 6 
lymph node are involved[12,20]. In T1N3a cases, the 
risk of recurrence could exceed 50%, reaching 80% in 
pT1N3b[22]. In Western patients, EGC with advanced 
nodal status should be considered very aggressive 
forms, requiring appropriate surgical and adjuvant 
treatments.
Early forms could also be treated by minimally-
invasive (laparoscopic or robotic) approach, which 
demonstrated non-inferior oncological results than 
open surgery in recent studies[23,24]. However, it should 
be emphasized that oncological criteria regarding 
resection margin and lymph node dissection need to 
be carefully followed in minimally-invasive procedures.
D2 LYMPH NODE DISSECTION FOR 
ADVANCED GASTRIC CANCER
Gastric cancer is one of the leading causes of death for 
cancer worldwide[25,26]. In the latest decades in Eastern 
countries national screening programs have brought 
to earlier and widespread diagnosis while in Western 
countries diagnosis is often late, due to the lack of 
surveillance strategies[27]. In all the cases surgery is 
indeed the standard of care for all resectable tumours: 
radical gastrectomy with regional lymphadenectomy is 
considered the adequate treatment[28]. 
Gastric cancer has a high tendency to lymph 
nodes involvement and local spread: the deeper is the 
extension of the tumour the more they are invaded[29]. 
Nodal spreading gradually takes place radiating from 
the primary site[30,31] and nodal involvement is one of 
the most important prognostic factors. It is therefore 
clear the reason why surgeons have always given 
so much importance to lymphadenectomy and its 
extension
In fact, lymph node dissection has been debated for 
several years by surgeons: as a result, two different 
schools have developed[32,33]. In Eastern countries 
D2 lymphadenectomy has been considered the 
standard procedure since the 60’s[34,35], in particular in 
Japan[1,36,37], where the high incidence of this tumour 
has always raised great interest. In Asian countries 
extended lymphadenectomy seems to give superior 
results in terms of survival and recurrence[38-42]: 
this could be explained by the Asian larger surgical 
experience with this kind of dissection[18,38,43-46] and by 
the younger age of Asian patients, who therefore have 
fewer comorbidities[38,47], and less abdominal fat with 
a consequent easier feasibility of the procedure[46]. 
A criticism that Western surgeons have advocated is 
that Japanese- and Asian in general-results were often 
provided by retrospective surveys and non-randomized 
studies[38,45,48].
On the contrary in Western countries D2 lympha-
denectomy was not considered a standard procedure 
in the clinical practice[27,35,43]: the lower incidence of 
this tumour and the consequent less confidence of 
western surgeons in this procedure is surely one of 
the reasons. D2 is a complicated and challenging 
surgical technique and a proper training is mandatory. 
In addition, according to former studies [mainly 
Western randomized clinical trials (RCTs)[38,45,46,49] and 
subsequent reviews[50-54]] D2 seemed associated with 
higher rate of surgical complications and higher peri-
operative mortality, without a real survival benefit. 
Driven by these results, Western surgeons have always 
preferred the limited dissection.
Recent data have undermined this historical 
preference and started to change Western point of 
view on D2 lymphadenectomy. In fact it has been 
demonstrated[28,45-48,55-58] that the higher rate of 
mortality and surgical complications with D2 procedure 
were mostly related to distal pancreatectomy and/
or splenectomy, which previously were included in 
the standard D2 lymphadenectomy and considered 
necessary for an adequate nodal dissection. Older 
studies[18,36,44,47-52] included in the D2 group all patients 
treated with distal pancreatectomy and splenectomy: 
these patients had a higher mortality rate and a 
higher incidence of surgical complications (such as 
fistulas, re-intervention, anastomotic leakage etc.) 
which influenced their outcome. On the contrary in 
more recent studies[18,28,43,44,53] subsites of patients that 
underwent splenopancreatectomy and patients with 
spleen and/or pancreas preservation are analysed 
separately.
Furthermore it has been shown that even in 
Western countries, after a proper training, surgeons 
can safely perform a D2 gastrectomy when spleen and 
pancreas are preserved, leading to lower morbidity 
and mortality rates and to a safer lymph node 
dissection[18,44,58]. 
Last but not least the 15 year-follow up of the 
famous Dutch study[28] has demonstrated that loco-
regional recurrence rate is significantly lower in 
patients treated with D2 lymphadenectomy vs patients 
who underwent D1 dissection, showing a survival 
benefit with the enlarged dissection.
Here after some of the most significant studies, 
RCTs, reviews and meta-analysis -over D1 vs D2 are 
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reported.
Dent et al[59] in 1988 described the first RCT 
recruiting 43 patients, 22 with D1 and 21 with D2 
dissection: the D2 group showed a higher rate of 
perioperative complications without any significant 
benefit in survival after a follow up of three years.
In the 90’s two multicentre European RCTs, the 
Dutch and the MRC trials, almost simultaneously, 
published their results comparing short and long-term 
outcomes after D1 and D2 LN dissection. In the Dutch 
trial[45], which randomised 711 patients (380 to D1 and 
331 to D2), the D2 group showed a higher mortality 
rate (10% vs 4%, p = 0.004), a higher frequency of 
postoperative complications (43% vs 25%, p < 0.001) 
and a longer hospital stay (median 25 d vs 18 d, p 
< 0.001). In 1999 the same authors[46] reported the 
5-year survival results: survival rates were similar in 
the two groups (45% in D1 vs 47% in D2). The risk 
of relapse after 5 years was 43% for the D1 group 
and 37% for the D2 group; the difference suggested 
only a trend of survival benefit for the D2 group (p 
= 0.22). In addition, patients who needed resection 
of the spleen or of the distal pancreas had a lower 
survival rate compared to those who did not require 
it; splenectomy was found to be an independent risk 
factor for surgical complications[60] and was associated 
with decreased survival in both D1 and D2 procedures. 
The authors concluded that splenectomy should not be 
a routine part of the standard gastrectomy.
In 2004 the Dutch Gastric Cancer Group published 
the long-term outcome of their trial[48] after 11 years 
follow-up: no overall survival benefit was demonstrated 
with D2 lymphadenectomy (30% with D1 vs 35% with 
D2, p = 0.53) and only in subgroup analysis patients 
with N2 disease showed higher survival rate after D2 
than after D1procedure. The authors concluded that 
no overall survival benefit had been demonstrated 
with an extended dissection as the associated higher 
postoperative mortality may had offset D2 long-term 
benefit in survival; for that reason D2 dissection could 
have been of benefit only if mortality and morbidity 
could have been avoided.
In 2010 the results of 15-year follow-up of the 
same trial[28] were published. D2 lymphadenectomy 
was finally associated with lower loco-regional 
recurrence and gastric-cancer-related death rates, 
as compared to those of D1 (p = 0.01). Significantly 
lower overall survival was noticed in patients who 
underwent splenectomy and pancreatectomy in both 
D1 and D2 groups. Subgroup analysis of patients who 
did not undergo pancreatectomy and splenectomy 
showed significantly higher overall 15-year survival 
rate in the D2 group (35% vs 22%). The authors 
concluded that, since other studies[61,62] had recently 
demonstrated that even in Europe trained surgeons 
could safely perform D2 lymphadenectomy with 
spleen and pancreas preservation and that D2 showed 
more favourable recurrence pattern and cancer-
related survival, D2 seemed to be the recommended 
treatment for patients with resectable gastric cancer 
(Table 3). 
In the british study[38], whose short term survival 
results were published in 1996, 400 patients, 200 with 
D1 and 200 with D2, were recruited. The D2 group 
had greater postoperative mortality (13% vs 6.5%, p 
= 0.04), higher overall postoperative morbidity (46% 
vs 28%, p < 0.001) and longer hospitalization. Also 
Cuschieri et al[49] investigated the adverse effects of 
distal pancreatico-splenectomy, reporting that the 
disadvantages of D2 gastrectomy (i.e., higher mortality 
and morbidity) might be the result of the additional 
pancreatectomies and splenectomies performed. The 
same authors in 1999 published the 5-year survival 
results of their trial[49] without showing any significant 
difference in the overall survival (35% in D1 and 
33% in D2). In multivariate analysis clinical stages Ⅱ 
and Ⅲ, male sex, old age and especially resection of 
spleen and pancreas were found to have a significant 
influence on survival. The authors concluded that D2 
gastrectomy did not offer any advantage in terms of 
survival over D1 gastrectomy and that pancreatico-
splenectomy should not be considered a part of D2 
dissection unless a direct involvement of the disease 
into the pancreas was suspected (Table 3). 
In 1998 the Italian Gastric Cancer Study Group 
published the results of a prospective multicentre 
phase 2 study on feasibility of D2 gastrectomy with 
spleen and pancreas preservation[61-63]: pancreatico-
splenectomy was not performed unless a direct 
involvement of the pancreas by the tumour was 
suspected. The authors showed that D2 gastrectomy 
with spleen and pancreas preservation could be done 
even in Western countries, in specialized centres, 
with a strict quality control and a after a period of 
adequate training. Mortality and morbidity rates 
were comparable to those of standard resection and 
even better, reaching figures similar to the Japanese 
ones. After these first cheering results, a randomised 
controlled trial was set up in 1998[58], in order to 
compare the short- and long-term outcome of D1 and 
D2 nodal dissection. A total of 267 patients with gastric 
cancer were randomly assigned to either a D1 (133) 
or a D2 (134) procedure with preservation of pancreas 
and spleen, in five specialized centres over a period of 
6 years. In 2010 the Authors reported the short-term 
results. In the intention-to-treat analysis, the overall 
morbidity rate after D2 and D1 dissections were 17.9% 
and 12.0% respectively (p = 0.178). The postoperative 
in-hospital mortality rate was 3.0% in the D1 group 
and 2.2% after D2 gastrectomy (p = 0.722). The 
Authors concluded that in specialized centres the rate 
of complications following D2 dissection was much 
lower than in published randomized Western trials 
and therefore D2 dissection, in an appropriate setting, 
could be considered as a safe option for the radical 
management of gastric cancer in Western patients. In 
2014 the Italian Gastric cancer Study Group published 
the long-term results of this RCT[18]. The five-year 
2882 March 14, 2016|Volume 22|Issue 10|WJG|www.wjgnet.com
Degiuli M et al . Lymph node dissection in gastric cancer
overall survival (OS) and disease-specific survival 
(DSS) rates were respectively 66.5% and 71% for 
D1 and 64.2% and 72.6% for D2, with no significant 
difference between the two groups (OS p = 0.695, 
DSS p = 0.916). Subgroup analysis showed a trend 
towards benefit of D2 dissection in patients with locally 
advanced gastric cancer (DSS 55% for D1 vs 69% 
for D2 with p = 0.143) and in patients with positive 
lymph nodes (OS rate 35% for D1 vs 51% for D2 and 
DSS rate 38% for D1 vs 59% for D2). This survival 
benefit was even greater and close to reaching a 
statistical significance in the subgroup of patients with 
both these two variables (T2-T4, N positive): 5-year 
OS rate was 35 % for D1 and 51% for D2, with p = 
0.078, while 5-year DSS was 38% for D1 and 59% for 
D2 (p = 0.055). Therefore the authors concluded that 
D2 might be a better choice in patients with advanced 
disease and lymph nodes metastasis (Table 3). 
Wu et al[55] in 2004 published the first results of a 
trial comparing 110 patients undergoing D1 dissection 
and 111 undergoing D3 resection and their respective 
morbidity and mortality rates. The postoperative 
hospital stay was longer for D3 patients [mean (SD) 
19.6 (13.9) (range 10-98) d vs 15.0 (4.0) (range 
10-30) d, p = 0.001]. Morbidity rate was higher in 
the D3 group (17.1% vs 7.3%, p = 0.012), mainly 
due to a high incidence of abdominal abscess after 
D3 resection (8.1% vs 0%, p = 0.003). Patients with 
hemipancreaticosplenectomy had a higher morbidity 
rate (35.7% vs 10.6%, p = 0.017). In both group 
there was no operative mortality. The study confirmed 
the higher risk of complications after that extensive 
dissections and suggested that extensive lymph node 
dissection should be done by surgeons thoroughly 
experienced in the technique. In 2006 the same 
authors[56] published the 5-year survival results: overall 
5-year survival was higher for D3 patients (59.5% 
vs 53.3%, p = 0.041). The authors concluded that 
even if D3 lymphadenectomy was associated with 
a higher morbidity, due to its surgical complexity, it 
had a significant long-term survival benefit over D1 
dissection (Table 3). 
Seevaratnam et al[57] in 2012 analysed 5 randomized 
trials involving 1642 patients (845 D1 and 797 D2) 
enrolled from 1982 to 2005; the authors highlighted 
the differences among earlier (considering procedures 
with spleen and pancreas removal) and more recent 
trials (with spleen and pancreas preservation). As 
concerns the short-term outcomes, overall hospital 
mortality was significantly higher for D2 patients (7.5% 
vs 3.8% with RR of 2.02, p = 0.002); subsite analysis 
showed that hospital mortality was still significantly 
higher for D2 patients in early trials (10.5% vs 4.6%, 
p = 0.0003), while it was similar in recent trials (1.5% 
for D1 vs 1.2% for D2, p = 0.70).
The overall 5-year survival rate showed similar 
results for D1 and D2 patients (43.5% and 44.9%, 
p = 0.58). In subgroup analysis no significant 
difference was found between T1/T2 patients (55.4% 
for D1 and 52.3% for D2, p = 0.46) while a trend 
of survival benefit in favour of D2 was identified for 
more advanced tumours (13.5% for D1 vs 19.5% for 
D2 in patients with T3/T4). In addition, the subgroup 
of patients with spleen and pancreas preservation 
showed a trend towards better survival rate with D2 
compared to D1 (54.9% vs 43.0%). The authors 
concluded that while older trials favoured D1, the more 
recent trials did not show any significant differences in 
mortality between the two procedures, demonstrating 
that D2 gastrectomy could be performed safely, mostly 
due to the preservation of spleen and pancreas.
In 2014 Jiang et al[35] analysed 8 RCTs published 
between 1988 and 2010, with a total of 2044 patients 
(1042 D1 and 1002 D2). D2 gastrectomy resulted 
associated with significantly greater morbidity in 
terms of anastomotic leakage, pancreatic leakage, 
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Table 3  Results of randomised controlled trials on D1 vs  D2 gastrectomy
RCT Nr. pts Morbidity (%) Mortality (%) Survival (%)
D1 D2 D1 D2 D1 D2 D1 (OS) D2 (OS)
Bonenkamp et al[45,46] 380 331 25 43 
p < 0.001
4 10 
p = 0.04
45 (5 yr) 47 (5 yr) 
p = 0.99
30 (11 yr) 35 (11 yr) 
p = 0.53
21 (15 yr) 35 (15 yr) 
p = 0.03
Cuschieri et al[38,49] 200 200 28 46 
p < 0.001
   6.5 13 
p = 0.04
35 (5 yr) 33 (5 yr) 
p = 0.43
Wu et al[55,56] 110 111    17.1 7.3 
p = 0.012
0 0 59.5 (5 yr) 53.3 (5 yr) 
p = 0.041
Degiuli et al[18, 58] 133 134 12 17.9 
p = 0.178
3 2.2 
p = 0.722
66.5 (5 yr) 64.2 (5 yr) 
p = 0.695
38 (DSS 5 yr 
T2-T4 N+)
59.0 (DSS 5 yr 
T2-4 N+) 
p = 0.055
RCT: Randomised controlled trial; OS: Overall survival; DSS: Disease specific survival; N+: Node positive patients.
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reoperation rates, wound infection and pulmonary 
complications. The overall 5-year survival rate did 
not show any significant difference between the 
two groups. Overall postoperative mortality was 
significantly lower in the D1 group (RR = 0.58, 95%CI: 
0.47-0.71, p < 0.001) but in subgroup analysis no 
difference was found between patients with pancreas 
and spleen preservation in D1 and D2 groups (RR = 
1.35, 95%CI: 0.45-4.05 for pancreas resection; RR = 
0.85, 95%CI: 0.47-1.54 for spleen resection), showing 
that the higher mortality associated with D2 in older 
trials was highly influenced by spleen and/or pancreas 
resection. The authors reported also a trend towards 
a lower risk of gastric cancer-related death in D2 
patients with spleen and pancreas preservation.
Anyway, in the latest years the consensus on D2 
lymphadenectomy has increased worldwide[28,57,64-78], 
since a trend of improved survival among D2 patients 
was recorded and published mainly due to spleen and 
pancreas preservation and to the increase of skillness 
and experience on D2 technique in high volume 
reference hospital.
Evidence based medicine (EBM) and practical 
surgical experience seem now to move towards an 
international agreement: nowadays D2 procedure 
is recommended as the standard procedure by the 
Japanese[3], Korean[10], German[79], british[80], Italian[81], 
European Society for Medical Oncology (ESMO)[82] and 
the joint ESMO- ESSO (European Society of Surgical 
Oncology)- ESTRO (European Society of Radiotherapy 
and Oncology) guidelines[83]; in addition, more recently 
NCCN recommends D1+ or modified D2[84] also in the 
United States.
D2+ FOR ADVANCED GASTRIC CANCER
Whether the extension of lymphadenectomy beyond 
the standard D2 dissection could add any benefit in the 
treatment of advanced gastric cancer, is a controversial 
issue.
The routine lymphadenectomy of para-aortic 
nodes (PAN), which has been practiced extensively by 
Japanese surgeons and in specialized Western centres 
in the past decades, is currently no more indicated 
after the publication of the Japan Clinical Oncology 
Group (JCOG) 9501 trial[85]. Indeed, the results of the 
Japanese trial showed no survival benefit after D2 plus 
PAN dissection compared to D2 lymphadenectomy 
alone in advanced gastric cancer without clinical 
suspicion of PAN metastases[85].
Nevertheless, in the JCOG9501 trial, a rather high 
5-year survival (18.2%) was reported in patients 
with positive PAN after a prophylactic PAN dissection. 
Also, similarly, in some Eastern and Western series, 
including cases with clinical involvement of PAN, long-
term survivals were reported, after PAN dissection, in 
patients with pathologically positive PAN[86], especially 
in the absence of incurable factors[87].
Therefore, some authors suggested the need of 
further evaluations before definitively rule out the 
PAN dissection by therapeutic options for treatment of 
advanced gastric cancer[88,89].
Interestingly, in a recent phase Ⅱ trial from the 
Stomach Cancer Study Group of the Japan Clinical 
Oncology Group[90], patients with locally advanced 
gastric cancer with extensive regional (N2) nodes 
and/or PAN metastases were treated with neo-
adjuvant chemotherapy (S-1 plus cisplatin) followed 
by extended surgery with PAN dissection. The 3- and 
5-year overall survival rates were of 59 and 53 per 
cent, respectively.
based on these results, Japanese surgeons are 
now suggesting that extended D2 plus PAN dissection 
after neo-adjuvant chemotherapy could be considered 
as a promising treatment for patients with clinically 
detected PAN involvement or with extensive N2 nodal 
metastases[91].
Anyway, we need further evaluations regarding 
the benefit of dissecting nodal stations other than PAN 
whose removal is currently no more indicated, and the 
identification of subgroups of advanced gastric patients 
who may definitely benefit from D2+ dissection after 
neo-adjuvant chemotherapy.
Indeed, according to the last version of Japanese 
guidelines[4], the standard D2 dissection does not 
include the removal of lymph nodes along the superior 
mesenteric vein (No. 14v). Of note, No. 14v station 
was comprised in the N2 compartment for lower third 
gastric tumours in the second edition of Japanese 
Classification[3] and was part of the D2 dissection for 
distal tumours in the JCOG9501 trial.
But, even in the lack of specific evidences a D2+ 
No 14v nodes is, currently, considered only in case 
of tumours with apparent metastases to infra-pyloric 
nodes. Recently, a Korean study[92] showed that 14v 
lymph node dissection was an independent prognostic 
factor in patients with clinical stage Ⅲ/Ⅳ gastric 
cancer of the middle and lower third, therefore future 
investigations on this topic are necessary.
Also, the dissection of posterior nodal stations (No. 
8p, 12p, 13), which were routinely removed during a 
super-extended (D3) lymphadenectomy and, in case 
of retro-pancreatic (No. 13) nodes, were comprised 
in the standard D2 dissection for distal tumours in the 
JCOG trial, is at present, no more indicated.
In a recent observational study of our GIRCG 
group, super-extended (D3) lymphadenectomy 
which included the systematic removal of posterior 
stations (8p, 12p, 13, 16a2 and 16b1), was 
associated with a significant lower incidence of loco-
regional relapses when compared to the standard 
D2 dissection in advanced gastric cancer with 
mixed-diffuse histology[93]. These results suggest a 
possible therapeutic role of the dissection of posterior 
stations other than PAN (8p, 12p. 13). Moreover, we 
observed that subgroups of tumours with a greater 
lymphotropism are better controlled by a super-
extended lymphadenectomy. In our study none of the 
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patients had received preoperative chemotherapy.
based on these findings, dedicated randomized 
trials are needed to provide specific evidences on 
the optimal extension and the indications of D2+ 
lymphadenectomy after neo-adjuvant chemotherapy 
in advanced gastric cancer.
LAPAROSCOPIC LYMPH NODE 
DISSECTION
In recent years, through the development of minimally 
invasive techniques and improvement of the devices 
for laparoscopic surgery, several surgeons have started 
applying laparoscopic assisted gastrectomy (LAG) for 
gastric cancer.
Although several potential benefits of LAG compared 
to conventional open procedure - such as less post-
operative pain, cosmetics, less blood loss, faster 
recovery, and shorter hospital stay - minimal invasive 
surgery for gastric cancer has not yet achieved a 
solid evidence-based validation; up to 2010, the 
Japanese Gastric Cancer Treatment Guidelines did not 
recommend LAG in a curative cancer resection setting, 
but indicated laparoscopic gastrectomy just as an 
investigational procedure eligible for clinical trials[4]. 
To date, two prospective trials (KLASS 01, JCOG 
0703)[94,95] and several retrospective studies argue 
the safety and oncological feasibility of laparoscopic 
surgery for the treatment of EGC. The results of these 
studies demonstrate both the reliability of laparoscopic 
lymphadenectomy in terms of oncological radicality as 
well as the absence of differences in the complication 
rate and short-term results between laparoscopic and 
open surgery. Therefore, along with the demonstration 
that the number of harvested lymph nodes by LAG to 
date has increased up to reach that observed during 
open gastrectomy, laparoscopic gastric surgery has 
now to be considered at least as “feasible”.
Most recent reports investigating the short-term 
results of laparoscopic gastric surgery refer to EGC; 
these data obviously can not be directly transferred to 
what is expected for advanced gastric cancer (AGC) 
and it is extremely important to differentiate the 
results related to early tumors from those related to 
advanced tumors.
EGC
As concerns early gastric cancer a phase Ⅲ multicenter 
prospective randomized trial (KLASS Trial)[94] has 
concluded that there is no significance difference in 
morbidity and mortality between laparoscopy assisted 
distal gastrectomy and open distal gastrectomy. 
Possible disadvantages are the longer operative time 
and the steep learning curve for laparoscopic surgery.
The same group to provide background data 
for KLASS trial, present one of the largest case-
matched series, comprising about 3000 patients with 
surgically resectable gastric cancer (approximately 
1500 laparoscopic and 1500 open gastrectomies over 
a 7-year period), comparing the long-term results of 
laparoscopic with open approach[96].
In this study, at a median follow-up of 70.8 mo 
the overall survival, disease-specific survival, and 
recurrence-free survival were not statistically different 
except for patients with stage IA disease treated with 
laparoscopic surgery, who showed an increased overall 
survival rate (laparoscopic group; 95.3%, open group: 
90.3%; p < 0.001) probably attributable to selection 
bias.
It is well known that the number of lymph nodes 
removed during gastrectomy is to be correlated with 
the prognosis of gastric cancer. In past years the 
number of lymph nodes collected during laparoscopic 
lymphadenectomy was lower compared to open 
lymphadenectomy. In recent years, through the 
improvement of laparoscopic surgical techniques and 
skills of surgeons, the number of dissected lymph 
nodes has gradually increased, reaching that observed 
after open gastrectomy.
Ohtani et al[97] in a meta-analysis conducted on 
four randomized control studies[97-100] comparing 
laparoscopic distal gastrectomy LADG with open 
distal gastrectomy (ODG) for EGC, has shown that 
the number of harvested lymph nodes was higher 
in the ODG group than in the LADG group, although 
this difference was not statistical significant except 
in one of the four studies. A recent meta-analysis of 
eight case-control studies has revealed that there is 
no evident difference in the number of lymph nodes 
dissected, between LADG and ODG[101]. The mean 
operative time for LADG is significantly higher than 
ODG. Kodera et al[102] has shown that the mean 
operating time in the LADG group ranged from 196 to 
348 min, that appears to be certainly longer than the 
time needed to accomplish an ODG in all studies. This 
finding could be due to the reduction of the field of 
view, lack of tactile sensation, and the steep learning 
curve needed for LADG. In the near future, with the 
advancements in surgical techniques and laparoscopic 
devices, the time required for laparoscopic-assisted 
gastrectomy is probably going to decrease.
Laparoscopic total gastrectomy
Differently from LADG, techniques for laparoscopic 
total gastrectomy (LTG) has not yet been standardized, 
therefore it remains a challenging procedure. Some 
technical difficulties involved in D2 lymphadenectomy, 
such as a safe dissection of the No. 10 lymph nodes, 
and a standardized laparoscopic anastomosis technique, 
may constitute an obstacle in applying laparoscopic 
surgery for proximal cancer.
A recent metanalysis[103] including eight non-RCTs 
was published. There were compared the short term 
results of 314 LTG and 384 open total gastrectomy 
(OTG) in patients with gastric cancer. In hospital 
mortality rates were comparable between two groups 
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(LTG 0.9% - OTG 1.8%). 
Patients in LTG group, despite a longer operative 
time, seem to have less intraoperative blood loss, less 
postoperative complications, and shorter hospital stay 
compared with OTG.
The results of this metanalysis showed that LTG 
has better short-term outcomes compared with OTG. 
Despite these encouraging results data on LTG are still 
limited. In South Korea, a multicenter phase Ⅱ trial 
(KLASS-03) trying to assess the feasibility of LTG for 
stage I gastric cancer is currently ongoing.
AGC
Another issue requiring further clarification is the 
application of laparoscopic surgery in AGC. Thus, if 
laparoscopy gastrectomy (LADG) has been increasingly 
used for EGC and T1-T2 tumors, still it has been less 
investigated as regards AGC; it is currently matter 
for debate if LAG with D2 lymphadenectomy should 
represent an appropriate treatment for an AGC as 
well[104,105]. Challenging technical issues could be 
represented by large-size tumors or tumors that 
require multiorgan resection.
To date, short-term results and complication 
rate of laparoscopic gastrectomy with D2 lymph 
nodes dissection for advanced gastric cancer are 
still controversial. Many authors have reported no 
difference between laparoscopic and open procedures 
in terms of number of harvested lymph nodes[106-108]. 
Shuang et al[109] has reported a median number of 
35 lymph nodes dissected in the laparoscopic group 
vs 38 in the open group, which is comparable to the 
number reported by other authors who performed 
laparoscopic surgery for AGC[107,110,111]. Analyzing the 
data in literature the postoperative morbidity rates of 
LAG for advanced gastric cancer ranges from 7.7% 
to 31.5%[94,112,113]. Cai et al[114] has reported that 
the overall morbidity rates were 12.24% in the LAG 
and 19.15% in the OG groups, with no significant 
difference. However, respiratory complications were 
more frequent in the OG group.
Learning Curve
Another important issue for laparoscopic lympha-
denectomy is the learning curve. In a recent korean 
series, in order to improve lymphadenectomy skills 
and decrease complications at least 42 gastrectomies 
were required[96]. 
Therefore, an extensive case-load is required 
to individual surgeons in order to perform a safe 
laparoscopy assisted gastrectomy; a precise standar-
dization of laparoscopic procedures together with 
a considerable number of cases are needed for an 
efficient educational system. Only the high-volume 
certified centers can provide the number required to 
the clinical application and teaching of laparoscopic 
techniques for gastric cancer[115]. 
The achievement of reliability of laparoscopic lympha-
denectomy in terms of oncological appropriateness and 
the absence of differences as regards the incidence of 
complications and short-term results between laparoscopic 
and open approach, have allowed the transferral of 
the many advantages of mini-invasiveness to the 
treatment of early gastric cancer. This has been made 
possible through the development of newly designed 
operative techniques and the introduction of better 
technological devices for laparoscopic surgery together 
with the undoubted improvement of surgical skills. 
Up to date laparoscopy assisted gastrectomy with D2 
lymph node dissection for the treatment of advanced 
gastric cancer is a promising oncological procedure with 
adequate lymph node harvesting. The advantages of 
minimal invasion, including the reduced risks of surgical 
related trauma, the containment of blood loss, less 
postoperative pain and earlier recovery could lead to 
a reduction in complications for difficult patients such 
as those with advanced gastric cancer. Confirmation of 
the appropriateness and safety of laparoscopic assisted 
gastrectomy for patients with advanced gastric cancer 
are expected from the results of different prospective 
studies comparing the short- and long-term outcomes 
(KLASS 02, CLASS 01, JLSSG 0901), which are 
currently in progress.
ROBOT ASSISTED LYMPH NODE 
DISSECTION
Modern oncology offers a huge step forward in 
more effective treatment of a cancer using modern 
and advanced equipment to improve the quality of 
care[116-120]. The role of robotic gastric cancer surgery 
is increasing, but still no strong and clear evidence 
has been reported to support the superiority of this 
approach over others. Clearly it shows advantages in 
comparison with laparoscopic by the use of twisted 
instruments with 7 degrees of freedom and motion 
scaling, tremor filtering and 3D visualization images 
of high resolution. It is clear that laparoscopy led us 
with magnifying anatomical structures to perform 
more precise lymphadenectomy. Using laparoscopical 
approach surgeons had to face with limitation of 
movements, linear laparoscopic tools, tremor transfer 
of the surgeon’s hand to the tip of the forceps, and 2D 
visualization without proper sense of depth. Robotic 
surgery seems to solve all of these disadvantages. The 
high resolution image with 3D visualization technology 
is especially useful in infrapyloric, suprapancreatic area 
and splenic hilum, where an adequate recognition of 
tiny anatomical structures during lymphadenectomy is 
of the highest importance. The endowrist instruments 
might be especially helpful during lymphadenectomy 
in suprapancreatic area where it seems to be more 
difficult in laparoscopic setting using linear instruments.
In retrospective studies in majority from eastern 
countries they compare laparoscopic and robotic 
approach sometimes also with open technique. Woo et 
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al[121] showed that robotic approach is associated with 
longer operative time. From the other hand less blood 
loss was observed during robotic surgery. Analyzing 
morbidity (11%) and mortality (0.4%) there were 
no difference between both techniques (p > 0.05). 
Also the numbers of dissected lymph nodes were 
similar. In paper by Kim et al[122] that compared overall 
complications, reoperation and mortality rates were 
similar in open, laparoscopic and robotic approach. The 
only difference was observed in anastomotic leakage 
which was more common in minimally invasive than 
in open approach (p = 0.017). It is probably because 
of usage staplers that were not used in minimally 
invasive techniques.
Currently we have few reviews and meta-analysis 
that analyzed problem of advantages in using robotic 
surgery during gastrectomy[123-127]. The results showed 
a lower amount of blood loss, but with longer time of 
operation. An explanations underline that the docking 
time might be responsible for prolonging the operation, 
and stable grasping and tissue retracting may help in 
better recognition of anatomical structures that lead to 
safer and less bloody procedure. The prolonged time 
of operation is also associated with more complicated 
lymphadenectomy especially with comparison to 
open technique. It is worth to note that no significant 
difference was observed according to the number 
of harvested lymph nodes. Also no difference was 
seen when analyzing overall complications rate and 
mortality.
Analyzing survival we have only 2 non randomized 
studies that compare robotic with open approach and 
one non-randomized study that compare laparoscopic 
and robotic one[128-130]. In publication by Caruso et 
al[130] no significant differences in overall survival rates 
was observed. Pernazza et al[128] proved that robotic 
surgery was associated with improved survival in 
comparison with open technique. This improvement 
was observed especially in advanced gastric cancer 
patients. In paper by Pugliese et al[129] 5-years survival 
was 85% for robotic and 75% for laparoscopic but 
without statistical significance.
Marano et al[127] analyzed technical benefits of robotic 
approach in gastric cancer surgery. They emphasized 
the improvement in performing lymphadenectomy in 
infrapyloric, suprapancreatic region, in splenic hilum 
and superior mesenteric vein. In paper by Son et al[131] 
where they compared spleen preserved robotic and 
laparoscopic D2 gastrectomy no difference between 
these two approaches was observed in terms of 
number of dissected lymph nodes, complications 
rate, and mortality rate. Interestingly they observed 
higher number of retrieved lymph nodes along splenic 
artery and splenic hilum in robotic approach. Higher 
number of retrieved lymph nodes was not associated 
with improvement in survival but of course led to 
improvement in staging of the disease. Seems that 
lower morbidity might be the most important benefit 
from robotic gastric cancer surgery. In paper by Suda 
et al[132] in comparison of laparoscopic with robotic 
approach the local complications rate (robotic vs lap 
1.1% vs 9.8%, p = 0.007) and morbidity (2.3% vs 
11.4%, p = 0.009) were statistically significantly lower 
as robotic technique was used. These authors underline 
the fact that in their series no pancreatic fistulas were 
reported. It is probably because of better anatomy 
visualization during lymphadenectomy and less 
traumatic access to the pancreatic parenchyma during 
robotic tissue preparation. In multicentric prospective 
study from South Korea the authors compared robotic 
with laparoscopic gastrectomy[133]. The complications 
rates were similar, without mortality in both arms. 
Robotic approach was associated with longer time of 
operation and higher costs. The authors conclude that 
perioperative surgical outcomes in robotic technique 
are not superior to laparoscopic one. Noshiro et al[134] 
analyzed using a monopolar scalpel in robotic lymph 
node dissection. They underlined a stable visualization of 
the operative field that can help in better understanding 
of the anatomy and proposed to use a term “robotically-
enhanced surgical anatomy”. The authors proved that 
robotic operation was associated with lower blood loss 
and lower rate of pancreatic fistula.
The most difficult part of widely usage a laparo-
scopic approach in gastric surgery is a complicated 
lymphadenectomy, and it is difficult to implement 
that into a routine practice[135]. It seems that usage 
of robotic may help in standardization of gastric 
cancer lymphadenectomy. The robotic approach may 
probably help in more precise and safer operation 
especially of some most critical lymph nodes stations 
like No. 6, 5, 1, 14v, and suprapancreatic area with 
stations 7, 8a and 9[136,137]. The greatest attention 
is directed to station nr 6 and suprapancreatic area 
because of its dissection is close to anterior surface of 
the pancreas. The anatomical differences in this area 
presented by Haruta et al[138] might be responsible for 
technical problems in this area. Any mistake in this 
area may lead to pancreatic parenchyma penetration 
followed by pancreatitis with local fistula and even a 
leakage if the duodenal stump[138]. Another difficult 
lymph node station dissection is number 10 in splenic 
hilum. Problems with bleeding in this area often lead 
to perform splenectomy. Robotic approach probably 
might help in better recognition of the anatomical planes 
and safer dissection even in mostly dangerous areas.
Another point of interest is a usage of robotic 
technique in obese patients especially that in western 
countries many patients show high body mass index 
(BMI) status. Theoretically obese patients may have a 
benefit form robotic approach because of technically 
demanding D2 lymphadenectomy especially around 
vessels when a fatty tissue might be a problem in 
adequate exposition of the surgical field. In paper by 
Park et al[139] patients were classified to obese and 
non-obese group according to visceral fat area (VFA). 
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Interestingly the complete number of total and N2 area 
lymph node number was higher in non-obese patients 
with VFA < 100 cm2. There were no differences 
in obese patients. Statistically significant robotic 
approach was associated with lower rate of severe 
complications after total gastrectomy in non-obese 
patients. The problem of obesity was also analyzed 
by Lee et al[140]. They compared subtotal gastrectomy 
with D2 lymphadenecotmy in laparoscopic and 
robotic approach in patients of different BMI status. 
In different BMI groups no significant difference in the 
rate of dissection of more than 25 nodes was observed 
between two techniques, but it is worth not note that 
laparoscopic approach had a significantly lower rate of 
retrieving more than 25 nodes in high BMI patients (p 
= 0.006). In high BMI patients the complications rate 
was comparable. 
Even as the role of extended lymphadenectomy 
in gastric cancer is still under debate no doubts this 
technique requires high level of experience. The full 
robotic interaortocaval nodal dissection was performed 
by the team Roviello et al[141] and proposed as a 
feasible technique in selected cases.
Another field of research and possible usage of 
robotic surgery in gastric cancer treatment is dissection 
of posterior lymph nodes during lymphadenectomy. 
In Siena University unpublished data the chances of 
metastases in stations 8p, 12p and 13 are 5.1%, and 
rise to 15.4% as we have a T3 tumor in distal part of 
the stomach- the latest data were presented during 
International Gastric Cancer Conference in Sao Paulo 
2015. This kind of lymphadenectomy is demanding 
and technically difficult in laparoscopic approach and 
in selected patients where the chances of cancer 
spread to these stations is the highest seems to be 
justified. From minimally invasive approach usage of 
robotic technique seems to be the optimal solution in 
this tailored treatment of advanced gastric cancer in 
western countries.
CONCLUSION
EGC can be successfully treated by endoscopic mucosal 
resection or endoscopic submucosal dissection, in 
reference centers with high operator and hospital 
volumes, when restricted or extended Gotoda's criteria 
can be applied and D1+ surgery is offered only to 
patients not fitted for less invasive treatment.
Furthermore, two randomised controlled trials have 
been demonstrating the non inferiority of laparoscopic 
technique as compared to standard open surgery for 
the treatment of early cases. Moreover, the feasibility 
of adequate D1+ dissection has been recently 
demonstrated also for the robot assisted technique. 
In case of AGC the debate on the extent of nodal 
dissection has been open for many decades. While D2 
gastrectomy was performed as the standard procedure 
in eastern countries, mostly based on observational 
and retrospective studies, in the west three RCTs (MRC, 
Dutch and IGCSG trials) have been conducted to show 
a survival benefit of D2 over D1 with EBM. While the 
MRC trial failed to show a survival benefit after the 
D2 procedure, mostly due to the significant increase 
of postoperative morbidity and mortality, which was 
referred to splenopancreatectomy, the Dutch trial 
could report a significant decrease of recurrence after 
D2 procedure at 15 years from the conclusion of its 
accrual. Recently, also the long term survival analysis 
of the Italian RCT could demonstrate a benefit for 
patients with AGC and positive nodes treated with D2 
gastrectomy without splenopancreatectomy. 
As nowadays also in western countries D2 pro-
cedure can be done safely with pancreas preserving 
technique and without preventive splenectomy, it has 
been suggested in several national guidelines as the 
recommended procedure for patients with AGC.
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